Randomized trials comparing Telmisartan vs. Valsartan and Losartan 24-hour ambulatory blood pressure control, GLP-1 heart failure outcomes, UKPDS 34 cardiovascular mortality reductions, and statin + ezetimibe ApoB targets. Explore 714 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
The optimal intervention should be targeted to cognitive decline in the early stages of dementia.
Higher SBPV and PPV were associated with greater risk of incident frailty.
Henagliflozin 5 mg and 10 mg as single-drug treatment provided effective glycaemic control, reduced body weight and blood pressure, and was generally well tolerated.
The time of onset of sustained BM frequency improvement mean and range are important when considering use of telotristat ethyl in patients with carcinoid syndrome diarrhea.
The getting both at the same time of multiple doses of telmisartan and rosuvastatin/ezetimibe led to a mild increase in systemic exposure with respect to telmisartan and rosuvastatin and a nonsignificant change in exposure to...
Azilsartan is an effective blood pressure lowering drug and well tolerated and was non- inferior to telmisartan in its safety and real-world benefits.
MDS TBR was - 6.2 ± 13.9% for patients in the ezetimibe/rosuvastatin group and - 10.8 ± 17.7% for those in the rosuvastatin group (difference, 4.6 percentage points; upper limitation of one-sided confidence interval = 13.8; p...
In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.
Similar to the VOYAGER meta-analysis, which reported a greater efficacy of rosuvastatin in comparison with atorvastatin and simvastatin in Caucasian patients, we found that the efficacy of rosuvastatin was superior to...
Statin use may not be associated with a lower risk of incidence and progression of OA, regardless of joint site.
Twelve-month use of E2/P4 had no clinically meaningful impact on weight or BP in postmenopausal women of the REPLENISH study.
Patients with higher doses had lower level of CK-MB, BNP, ALT, and TnI and lower occurrence of MACE after PCI.
OS significantly increased heart and blood vessel risk including the prevalence of high blood pressure and lung high blood pressure.
This meta-analysis reveals that statins significantly increase plasma Lp(a) levels.
Based on the effect on LDL cholesterol, pitavastatin is about 6-fold more potent than atorvastatin, 1.7-fold more potent than rosuvastatin, 77-fold more potent than fluvastatin and 3.3-fold less potent than cerivastatin.
The higher risks of heart attack and stroke in patients randomized to valsartan versus amlodipine were related to the drugs' different blood pressure modulating profiles.
Liraglutide seems to reduce GV in the acute phase of acute coronary syndrome, and patients achieved optimal control with a low incidence of low blood sugar.
Probabilistic sensitivity analysis and one-way sensitivity analyses showed the robustness of the model results.
Oral semaglutide can effectively and safely reduce blood glucose, body weight and systolic blood pressure.
Both RYGB and SG decrease carotid IMT in men with obesity compared with conventional treatment with diet and exercise.
Our meta-analysis indicated that following metformin treatment in patients with T2DM was associated with decreased heart and blood vessel risk, both with the mortality and incidence.
High-dose rosuvastatin or atorvastatin started upon hospital admission led to similar rates of AKI, 30-day kidney function changes, and 12-month death or MI in NSTE-ACS patients who underwent an early invasive strategy.
Beyond glucose control, SGLT2i reduce mGFR and filtration fraction in type 2 diabetes.
We confirmed the how the body absorbs the medicine equivalence of the FDC and LC treatments.
Twenty-seven subjects completed the study.
We reported that both statins similarly decreased the endocan levels, whereas rosuvastatin seems to have more prominent effects on the reduction of the chemerin and galectin-3 levels in patients with AMI.
1-year statin use versus control attenuated the progression of kidney function decline and proteinuria.
Statin-induced changes in cholesterol and proteinuria vary between individuals and do not run in parallel within an individual.
In patients with CAD and newly diagnosed T2DM on stable statin therapy, liraglutide combined with metformin may improve the atherogenic LDL lipid profile and CRP.
Women with polycystic ovary syndrome with metabolic syndrome have a negative impact from female fecundity, and this suggests an adverse effect on in vitro fertilization cycle stimulation characteristics and clinical outcomes.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
